Ann: Principal Investigator Discusses LuPIN-1 Study, page-2

The direct link to the interview is here...

https://www.finnewsnetwork.com.au/MediaCenter/MediaCenterMobile.aspx?Site=FNN1441

The interview deals with two therapies currently being used in clinical trials at St Vincent’s hospital in Sydney. The “theranostics” aspect of this interview is particularly interesting. This fairly new term is derived from combining the words therapy and diagnostics.

The really exciting aspect is that Novartis has just bought two companies in this Theranostics field and paid about $6Billion for them. Approximately $3.2Billion was for a company called Endocyte. Now Endocyte is supplying the drug that is being used in combination with our own Veyonda drug in one of these two trials. If it pans out that Veyonda can increase the efficacy of the Endocyte/Novartis drug.... well.... I’ll leave you to draw your own conclusions on what that might do to the Noxopharm shareprice in due course.

I’ll just leave you with this short piece from Dr Kelly.... you can hear this and all the rest of the current info in the video interview link above.

Apples


Dr Graham Kelly: As Louise has just explained, the field of theranostics is an emerging and exciting area in the whole field of cancer therapy. It’s a form of therapy that involves the use of radioactive drugs, or radiopharmaceuticals. And the evidence of this becoming a major area is shown in the fact that Novartis (SWX:NOVN) last year in 2018, spent $6 billion on acquiring two smaller companies. Now our hope is that Veyonda (formally known as NOX66) will become a companion drug, to be used in this field of theranostics.